Lebbé, C., Dutriaux, C., Lesimple, T., Kruit, W., Kerger, J., Thomas, L., . . . Dréno, B. (2020). Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. MDPI AG.
Chicago Style (17th ed.) CitationLebbé, Celeste, et al. Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. MDPI AG, 2020.
MLA (8th ed.) CitationLebbé, Celeste, et al. Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. MDPI AG, 2020.
Warning: These citations may not always be 100% accurate.